Patent ID: 6342500
Filing Date: 2002-01-29
Classification: A61P,C07D,C07F

Abstract:
A pharmaceutical composition comprising an amount effective to inhibit the conversion of Amadori compounds to post-Amadori advanced glycation endproducts or for treating or preventing an AGE-related pathology selected from the group consisting of proteinuria, impaired glomerular clearance, diabetic nephropathy, and protein cross-linking, of a compound of the formula wherein R1, R1â€², R5, and R5â€² are independently selected from the group consisting of (CH2)nX wherein n is between 0 and 6 and X is selected from the group consisting of H, OH, CH2OH, and mono-, di-, or tri-halogenated C1-6 alkyl; with the proviso that at least one of R1, R1â€², R5, and R5â€² is OH; wherein R2, R2â€², R4 and R4â€² are independently selected from the group consisting of (CH2)nZ, wherein n has the meaning given above and Z is selected from the group consisting of H, OH, and mono-, di-, or tri-halogenated C1-6; wherein R3 and R3â€² are independently selected from the group consisting of H and mono-, di-, or tri-halogenated C1-6 alkyl; wherein R6 and R6â€² are (CH2)x, wherein x is between 1 and 6; wherein R7 is selected from NH and HOP&boxH;O; or wherein R6, R6â€², and R7 combine to form an aryl group, heteroaryl group, or or a pharmaceutically acceptable salt or prodrug thereof;and a pharmaceutically acceptable carrier.